4-aminopyridine has been researched along with Spinal Cord Injuries in 60 studies
Spinal Cord Injuries: Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A Phase I trial of 4-aminopyridine (4-AP) was carried out in 39 dogs referred to the veterinary teaching hospital with naturally occurring traumatic paraplegia or paraparesis." | 5.07 | The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. ( Bauer, MS; Blight, AR; Toombs, JP; Widmer, WR, 1991) |
| "Fampridine (EL-970; 4-aminopyridine), a potassium channel blocker, is in phase II development by Acorda for the potential treatment of spinal cord injuries and multiple sclerosis (MS) [385529]." | 4.80 | Fampridine Acorda Therapeutics. ( Darlington, C, 2000) |
| "Aminopyridines such as 4-aminopyridine (4-AP) are widely used as voltage-activated K(+) (Kv) channel blockers and can improve neuromuscular function in patients with spinal cord injury, myasthenia gravis, or multiple sclerosis." | 3.75 | Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. ( Chen, SR; Li, DP; Pan, HL; Wu, ZZ, 2009) |
| " The drug was rapidly absorbed with a tmax approximately 1 hour for both groups; tmax was independent of dose." | 2.71 | Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. ( Blight, AR; Devane, JG; Hayes, KC; Hsieh, JT; Katz, MA; Potter, PJ; Wolfe, DL, 2003) |
| " Fourteen (56%) patients had 26 adverse reactions." | 2.71 | Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. ( Arenas-Hernández, R; Castañeda-Hernández, G; Grijalva, I; Guízar-Sahagún, G; Ibarra, A; Maldonado-Julián, H; Mino, D; Salgado-Ceballos, H; Serra, O; Vidal-Cantú, G, 2003) |
| " Safety assessments: physical examinations, vital sign measurements, clinical laboratory tests, electrocardiogram recordings, and adverse events." | 2.71 | Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. ( Blight, AR; Cohen, R; Hayes, KC; Hsieh, JT; Katz, MA; Potter, PJ, 2004) |
| "The Ashworth scale of spasticity was significantly (p2 < 0." | 2.69 | Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. ( Brunnemann, SR; Delaney, GA; Hayes, KC; Hsieh, JT; Mason, D; Potter, PJ; Segal, JL; Tierney, DS, 1998) |
| " 4-Aminopyridine appears to be safe and relatively free from toxicity when administered orally over 3 months." | 2.69 | Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial. ( Brunnemann, SR; Charter, RS; Hernandez, JP; Himber, PL; Pathak, MS; Segal, JL, 1999) |
| " A statistically significant difference in the initial rate and extent of absorption, but not in total 4-AP bioavailability over the 12-hour study period, was evident between tetraplegic patients, 0." | 2.69 | Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury. ( Brunnemann, SR; Hayes, KC; Hsieh, JT; Mason, D; Pathak, MS; Potter, PJ; Segal, JL; Tierney, DS, 2000) |
| "Following animal mode studies to establish dosing safety, six subjects with chronic SCI were examined." | 2.69 | Intrathecal administration of 4-aminopyridine in chronic spinal injured patients. ( Blight, AR; Calvillo, O; Donovan, WH; Halter, JA, 2000) |
| "Severity of spasticity and H-reflex threshold might allow prediction of response." | 1.51 | Predictors of Response to 4-Aminopyridine in Chronic Canine Spinal Cord Injury. ( Laber, E; Lewis, MJ; Olby, NJ, 2019) |
| " With the use of a double sucrose gap-recording chamber we perform a dose-response assay to examine the effects of these compounds on axonal conduction following an in vitro stretch injury." | 1.33 | Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma. ( Borgens, RB; Byrn, SR; McBride, JM; Shi, R; Smith, DT, 2006) |
| " The dose-response characteristics of acutely and chronically injured axons were compared." | 1.30 | Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. ( Blight, AR; Kelly, TM; Shi, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.33) | 18.7374 |
| 1990's | 21 (35.00) | 18.2507 |
| 2000's | 27 (45.00) | 29.6817 |
| 2010's | 10 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Page, JC | 1 |
| Park, J | 1 |
| Chen, Z | 1 |
| Cao, P | 2 |
| Shi, R | 9 |
| Lewis, MJ | 1 |
| Laber, E | 2 |
| Olby, NJ | 2 |
| Wiener, J | 1 |
| Hsieh, J | 1 |
| McIntyre, A | 1 |
| Teasell, R | 1 |
| Cardenas, DD | 2 |
| Ditunno, JF | 1 |
| Graziani, V | 2 |
| McLain, AB | 1 |
| Lammertse, DP | 1 |
| Potter, PJ | 10 |
| Alexander, MS | 1 |
| Cohen, R | 3 |
| Blight, AR | 14 |
| Lim, JH | 1 |
| Muguet-Chanoit, AC | 1 |
| Smith, DT | 4 |
| Lombardi, G | 1 |
| Musco, S | 1 |
| Wyndaele, JJ | 1 |
| Del Popolo, G | 1 |
| Sindhurakar, A | 1 |
| Mishra, AM | 1 |
| Gupta, D | 1 |
| Iaci, JF | 1 |
| Parry, TJ | 1 |
| Carmel, JB | 1 |
| Wu, ZZ | 1 |
| Li, DP | 1 |
| Chen, SR | 1 |
| Pan, HL | 1 |
| Namur, S | 1 |
| González-de la Parra, M | 1 |
| Castañeda-Hernández, G | 4 |
| Grijalva, I | 3 |
| García-Pérez, A | 1 |
| Díaz, J | 1 |
| Aguilar, S | 1 |
| Mino, D | 2 |
| Santiago-Rodríguez, E | 1 |
| Guizar-Sahagún, G | 3 |
| Maldonado-Julián, H | 2 |
| Madrazo, I | 1 |
| Sun, W | 1 |
| Fu, Y | 1 |
| Shi, Y | 1 |
| Cheng, JX | 1 |
| Wickelgren, I | 1 |
| Isoda, WC | 1 |
| Segal, JL | 7 |
| Hayes, KC | 10 |
| Katz, MA | 2 |
| Devane, JG | 1 |
| Hsieh, JT | 9 |
| Wolfe, DL | 4 |
| Vidal-Cantú, G | 1 |
| Ibarra, A | 1 |
| Serra, O | 1 |
| Salgado-Ceballos, H | 1 |
| Arenas-Hernández, R | 1 |
| DeForge, D | 1 |
| Nymark, J | 1 |
| Lemaire, E | 1 |
| Gardner, S | 1 |
| Hunt, M | 1 |
| Martel, L | 1 |
| Curran, D | 1 |
| Barbeau, H | 1 |
| Taccola, G | 1 |
| Nistri, A | 1 |
| Borgens, RB | 4 |
| McBride, JM | 3 |
| Jackson, K | 1 |
| Byrn, SR | 3 |
| Ditunno, J | 1 |
| Jackson, AB | 1 |
| Lammertse, D | 1 |
| Potter, P | 1 |
| Sipski, M | 1 |
| Rodríguez-Pacheco, D | 1 |
| Francisco-Argüelles, C | 1 |
| Palma-Aguirre, JA | 1 |
| Thompson, JF | 1 |
| Tayek, JA | 1 |
| Knafo, S | 1 |
| Choi, D | 1 |
| Fehlings, MG | 4 |
| Nashmi, R | 4 |
| Haghighi, SS | 3 |
| Pugh, SL | 1 |
| Perez-Espejo, MA | 2 |
| Oro, JJ | 1 |
| Delaney, GA | 4 |
| Hansebout, RR | 1 |
| Fawcett, S | 1 |
| Reddy, K | 1 |
| Waxman, SG | 1 |
| Allatt, RD | 1 |
| Lam, S | 1 |
| Hamilton, JT | 1 |
| Adelstein, EH | 1 |
| Madsen, R | 1 |
| Zeidman, SM | 1 |
| Ling, GS | 1 |
| Ducker, TB | 1 |
| Ellenbogen, RG | 1 |
| Qiao, J | 1 |
| Kelly, TM | 1 |
| Clapper, A | 1 |
| Johnson, GC | 1 |
| Stevens, A | 1 |
| Prapaisilp, A | 1 |
| Brunnemann, SR | 4 |
| Tierney, DS | 2 |
| Mason, D | 2 |
| Gruner, JA | 2 |
| Yee, AK | 1 |
| Pathak, MS | 2 |
| Hernandez, JP | 1 |
| Himber, PL | 1 |
| Charter, RS | 1 |
| Jones, OT | 1 |
| Donovan, WH | 2 |
| Halter, JA | 2 |
| Graves, DE | 1 |
| Calvillo, O | 2 |
| McCann, MT | 1 |
| Sherwood, AM | 1 |
| Castillo, T | 1 |
| Parsons, KC | 1 |
| Strayer, JR | 1 |
| Darlington, C | 1 |
| van der Bruggen, MA | 1 |
| Huisman, HB | 1 |
| Beckerman, H | 1 |
| Bertelsmann, FW | 1 |
| Polman, CH | 1 |
| Lankhorst, GJ | 1 |
| Yu, K | 1 |
| Li, J | 1 |
| Rong, W | 1 |
| Jia, L | 1 |
| Yuan, W | 1 |
| Ye, X | 1 |
| Shi, Z | 1 |
| Dai, B | 1 |
| Pryor, JD | 1 |
| Nockels, R | 1 |
| Young, W | 1 |
| Toombs, JP | 1 |
| Bauer, MS | 1 |
| Widmer, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quality of Life, Efficacy and Safety of High Doses of 4-aminopyridine in Patients With Clinically Complete Chronic Spinal Cord Injury: Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial[NCT03899584] | Phase 3 | 150 participants (Actual) | Interventional | 2019-07-17 | Active, not recruiting | ||
| Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study[NCT02591901] | Phase 2 | 48 participants (Actual) | Interventional | 2018-04-06 | Completed | ||
| A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma[NCT04026568] | Phase 2/Phase 3 | 1 participants (Actual) | Interventional | 2021-08-17 | Terminated (stopped due to Study investigator left Institution) | ||
| Pharmaco-Diagnostic Crossover Trial for Peripheral Nerve Continuity After Trauma[NCT06003166] | Phase 3 | 68 participants (Anticipated) | Interventional | 2024-04-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Return of lost sensation after nerve injury attributable to circulating 4-AP. Subjective return of sensation in the injured limb or portion of the limb.~Patients for this trial are not able to sense in portions of their limbs. The measure will be sensation, measured on the binary scale of yes or no (able to feel the extremity versus unable to feel) This is assessed through clinical examination of the injured limb." (NCT04026568)
Timeframe: During dosing of drug intervention (5 hours) and 2, 6, 9, 12, 15, 20 weeks post injury
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return of sensation prior to administration of study drug-baseline | Return of sensation 1 hour post study drug administration | Return of sensation 2 hours post study drug administration | Return of sensation 3 hours post study drug administration | Return of sensation 4 hours post study drug administration | Return of sensation 5 hours post study drug administration | Return of sensation 2 weeks post injury | Return of sensation 6 weeks post injury | Return of sensation 9 weeks post injury | Return of sensation 12 weeks post injury | Return of sensation 15 weeks post injury | Return of sensation 18 weeks post injury | Return of sensation 20 weeks post injury | |
| Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NA | NA | NA |
9 reviews available for 4-aminopyridine and Spinal Cord Injuries
| Article | Year |
|---|---|
Effectiveness of 4-Aminopyridine for the Management of Spasticity in Spinal Cord Injury: A Systematic Review.
Topics: 4-Aminopyridine; Humans; Muscle Relaxants, Central; Muscle Spasticity; Potassium Channel Blockers; S | 2018 |
Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study.
Topics: 4-Aminopyridine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Erectile Dysfunction; H | 2015 |
Fampridine-SR for multiple sclerosis and spinal cord injury.
Topics: 4-Aminopyridine; Animals; Clinical Trials as Topic; Disability Evaluation; Drug Evaluation; Humans; | 2007 |
Clinical studies in spinal cord injury: moving towards successful trials.
Topics: 4-Aminopyridine; Animals; Biomedical Research; Clinical Trials as Topic; Female; Humans; Male; Potas | 2008 |
Aminopyridines and the treatment of spinal cord injury.
Topics: 4-Aminopyridine; Animals; Humans; Spinal Cord Injuries | 1993 |
Clinical applications of pharmacologic therapies for spinal cord injury.
Topics: 4-Aminopyridine; Animals; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; D | 1996 |
Fampridine Acorda Therapeutics.
Topics: 4-Aminopyridine; Animals; Clinical Trials as Topic; Contraindications; Drugs, Investigational; Human | 2000 |
Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels.
Topics: 4-Aminopyridine; Animals; Axons; Humans; Kv1.1 Potassium Channel; Kv1.2 Potassium Channel; Potassium | 2001 |
Pharmacologic strategies in the treatment of experimental spinal cord injury.
Topics: 4-Aminopyridine; Animals; Baclofen; Disease Models, Animal; Gangliosides; Humans; Lipid Peroxidation | 1992 |
24 trials available for 4-aminopyridine and Spinal Cord Injuries
| Article | Year |
|---|---|
Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Canada; Double-Blind Method; Female; Humans; Male; Muscle Spasticity; Potass | 2014 |
Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.
Topics: 4-Aminopyridine; Animals; Demyelinating Diseases; Dogs; Double-Blind Method; Female; Gait; Hindlimb; | 2014 |
Quantification of 4-aminopyridine in plasma by capillary electrophoresis with electrokinetic injection.
Topics: 4-Aminopyridine; Administration, Oral; Adolescent; Adult; Amifampridine; Electricity; Electrophoresi | 2010 |
High doses of 4-aminopyridine improve functionality in chronic complete spinal cord injury patients with MRI evidence of cord continuity.
Topics: 4-Aminopyridine; Adult; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Place | 2010 |
Effects of 4-aminopyridine on cardiac repolarization, PR interval, and heart rate in patients with spinal cord injury.
Topics: 4-Aminopyridine; Adult; Double-Blind Method; Electrocardiography; Female; Heart Conduction System; H | 2003 |
Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Area Under Curve; Biological Availability; Chromatogra | 2003 |
Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Chronic Disease; Dose-Response Relationship, Drug; Dou | 2003 |
Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Female; Huma | 2004 |
Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Aged; Analysis of Variance; Cross-Over Studies; Dose-R | 2004 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Phase 2 trial of sustained-release fampridine in chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2007 |
Effects of long-term 4-aminopyridine therapy on glucose tolerance and glucokinetics in patients with spinal cord injury.
Topics: 4-Aminopyridine; Adult; Glucose; Glucose Intolerance; Glucose Tolerance Test; Hospitals, Veterans; H | 2007 |
4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury.
Topics: 4-Aminopyridine; Adolescent; Adult; Electric Stimulation; Electromyography; Evoked Potentials, Somat | 1994 |
4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Electrophysiology; F | 1993 |
The effects of taxol, methylprednisolone, and 4-aminopyridine in compressive spinal cord injury: a qualitative experimental study.
Topics: 4-Aminopyridine; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Dose-Response Relationshi | 1996 |
Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury.
Topics: 4-Aminopyridine; Adult; Evoked Potentials, Motor; Female; Humans; Male; Middle Aged; Spinal Cord Inj | 1997 |
Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
Topics: 4-Aminopyridine; Adult; Analysis of Variance; Chi-Square Distribution; Cross-Over Studies; Delayed-A | 1998 |
4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Gait; Humans; Locomotion; Male; Paraplegia; Quadripleg | 1998 |
Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Aged; Central Nervous System; Cohort Studies; Double-B | 1999 |
Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury.
Topics: 4-Aminopyridine; Absorption; Adult; Area Under Curve; Biological Availability; Chronic Disease; Cros | 2000 |
Intravenous infusion of 4-AP in chronic spinal cord injured subjects.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Electromyogr | 2000 |
Intrathecal administration of 4-aminopyridine in chronic spinal injured patients.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Huma | 2000 |
Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial.
Topics: 4-Aminopyridine; Adult; Cross-Over Studies; Double-Blind Method; Electromyography; Evoked Potentials | 2001 |
Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury.
Topics: 4-Aminopyridine; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Huma | 2001 |
The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial.
Topics: 4-Aminopyridine; Animals; Dog Diseases; Dogs; Drug Evaluation; Muscles; Pain; Paraplegia; Propriocep | 1991 |
27 other studies available for 4-aminopyridine and Spinal Cord Injuries
| Article | Year |
|---|---|
Parallel Evaluation of Two Potassium Channel Blockers in Restoring Conduction in Mechanical Spinal Cord Injury in Rat.
Topics: 4-Aminopyridine; Aminopyridines; Animals; Male; Neural Conduction; Potassium Channel Blockers; Rats; | 2018 |
Predictors of Response to 4-Aminopyridine in Chronic Canine Spinal Cord Injury.
Topics: 4-Aminopyridine; Animals; Dogs; Evoked Potentials, Motor; Female; H-Reflex; Male; Motor Neurons; Mus | 2019 |
Clinically Relevant Levels of 4-Aminopyridine Strengthen Physiological Responses in Intact Motor Circuits in Rats, Especially After Pyramidal Tract Injury.
Topics: 4-Aminopyridine; Animals; Central Nervous System Agents; Cervical Cord; Drug Evaluation, Preclinical | 2017 |
Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit.
Topics: 4-Aminopyridine; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, N-Type; Calcium Chann | 2009 |
Changing the "channel": aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit.
Topics: 4-Aminopyridine; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, N-Type; Calcium Chann | 2009 |
Paranodal myelin damage after acute stretch in Guinea pig spinal cord.
Topics: 4-Aminopyridine; Action Potentials; Animals; Biotransformation; Calcium; Calcium Channel Blockers; C | 2012 |
Neuroscience. Animal studies raise hopes for spinal cord repair.
Topics: 4-Aminopyridine; Animals; Chondroitin ABC Lyase; Clinical Trials as Topic; Combined Modality Therapy | 2002 |
Electrophysiological effects of 4-aminopyridine on fictive locomotor activity of the rat spinal cord in vitro.
Topics: 4-Aminopyridine; Animals; Animals, Newborn; Biological Clocks; Gait Disorders, Neurologic; Locomotio | 2005 |
Development of novel 4-aminopyridine derivatives as potential treatments for neurological injury and disease.
Topics: 4-Aminopyridine; Animals; Carbamates; Disease Models, Animal; Drug Design; Drug Evaluation, Preclini | 2005 |
Dose responses of three 4-aminopyridine derivatives on axonal conduction in spinal cord trauma.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Carbamates; Disease Models, Animal; Dose-Respons | 2006 |
Gastric emptying effect by 4-aminopyridine in patients with chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Dyspepsia; Female; Gastric Emptying; Humans; Male; Middle Aged; Potassium Ch | 2007 |
4-Aminopyridine derivatives enhance impulse conduction in guinea-pig spinal cord following traumatic injury.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Carbamates; Cell Membrane; Cell Size; Female; Gu | 2007 |
Assessment of axonal dysfunction in an in vitro model of acute compressive injury to adult rat spinal cord axons.
Topics: 4-Aminopyridine; Animals; Axons; Disease Models, Animal; Evoked Potentials; Male; Myelin Sheath; Ner | 1995 |
Effect of 4-aminopyridine in acute spinal cord injury.
Topics: 4-Aminopyridine; Acute Disease; Animals; Disease Models, Animal; Evoked Potentials, Somatosensory; N | 1995 |
Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury.
Topics: 4-Aminopyridine; Adult; Blood Pressure; Body Temperature; Chronic Disease; Drug Evaluation; Electroe | 1993 |
Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Cesium; Chlorides; Electrophysiology; Male; Micr | 1996 |
Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine.
Topics: 4-Aminopyridine; Action Potentials; Acute Disease; Animals; Chronic Disease; Dose-Response Relations | 1997 |
Effect of 4-aminopyridine and single-dose methylprednisolone on functional recovery after a chronic spinal cord injury.
Topics: 4-Aminopyridine; Animals; Behavior, Animal; Chronic Disease; Glucocorticoids; Male; Methylprednisolo | 1998 |
Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord.
Topics: 4-Aminopyridine; Animals; Axons; Electrophysiology; Female; Guinea Pigs; Membrane Potentials; Myelin | 1997 |
Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases.
Topics: 4-Aminopyridine; Administration, Oral; Adult; Evoked Potentials, Motor; Female; Humans; Male; Middle | 1998 |
4-Aminopyridine enhances motor evoked potentials following graded spinal cord compression injury in rats.
Topics: 4-Aminopyridine; Animals; Evoked Potentials, Motor; Female; Linear Models; Nerve Compression Syndrom | 1999 |
Acute repair of crushed guinea pig spinal cord by polyethylene glycol.
Topics: 4-Aminopyridine; Animals; Electrophysiology; Female; Guinea Pigs; In Vitro Techniques; Nerve Crush; | 1999 |
Abnormal axonal physiology is associated with altered expression and distribution of Kv1.1 and Kv1.2 K+ channels after chronic spinal cord injury.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Cesium; Chlorides; Elapid Venoms; Female; Gene E | 2000 |
Recording of spared motor evoked potentials and its augmentation by 4-aminopyridine in chronic spinal cord-injured rats.
Topics: 4-Aminopyridine; Animals; Electric Stimulation; Evoked Potentials, Motor; Male; Potassium Channel Bl | 2001 |
Pathological changes of isolated spinal cord axons in response to mechanical stretch.
Topics: 4-Aminopyridine; Action Potentials; Animals; Axons; Cell Membrane; Cell Membrane Permeability; Disea | 2002 |
Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury.
Topics: 4-Aminopyridine; Action Potentials; Aminopyridines; Animals; Cats; Disease Models, Animal; Female; N | 1989 |
Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats.
Topics: 4-Aminopyridine; Aminopyridines; Animals; Cats; Chronic Disease; Efferent Pathways; Electromyography | 1987 |